DBV Technologies Reveals Stronger Phase 3 Peanut Allergy Data, Confirms H1 2026 BLA Submission

summarizeSummary

DBV Technologies presented additional positive data from its Phase 3 VITESSE study for the VIASKIN® Peanut Patch, showing significant desensitization in children and confirming plans for a Biologics License Application (BLA) submission in the first half of 2026.

check_boxKey Events

• Additional Positive Phase 3 Data

  New data from the VITESSE study showed 82.8% of children treated with VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to 48% in the placebo group.

• Significant Desensitization Observed

  60.1% of treated children increased their eliciting dose by at least two doses, while only 6.4% saw a decrease, compared to 24% in the placebo group.

• BLA Submission Confirmed

  The company reiterated its plan to submit a Biologics License Application (BLA) for the VIASKIN® Peanut Patch to the FDA in the first half of 2026.

auto_awesomeAnalysis

This 8-K highlights robust additional data from the successful Phase 3 VITESSE study, reinforcing the efficacy and safety profile of the VIASKIN® Peanut Patch for peanut-allergic children. The detailed results, showing a high percentage of children increasing their eliciting dose and a low percentage experiencing decreased tolerance, strengthen the product's clinical profile. The explicit confirmation of a Biologics License Application (BLA) submission to the FDA in the first half of 2026 provides a clear regulatory timeline, which is a critical de-risking event for a late-stage biopharmaceutical company. This positive development could significantly advance the company's path to commercialization and address a substantial unmet medical need.